Maximiliano Klug
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maximiliano Klug has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Zehavit Kirshenboim
Division of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
7 shared publications - Edith Michelle Marom
Division of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
6 shared publications Eli Konen
Division of Diagnostic Imaging, The Chaim Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
4 shared publications- Mylene T. Truong
Department of Thoracic Imaging, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
4 shared publications - Chad D. Strange
From the Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1478, Houston, TX 77030
3 shared publications Efrat Ofek
3 shared publications
Latest Publications
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (5) , e250144
The Ninth Edition TNM Staging System for Thymic Epithelial Tumors: A Comprehensive Review
The ninth edition of the TNM classification for thymic epithelial tumors, effective January 2025, introduces updated criteria for tumor extent, lymph node involvement, and metastasis, reinforcing the critical role of imaging in accurate staging and treatment planning.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (5) , e250144
The Ninth Edition TNM Staging System for Thymic Epithelial Tumors: A Comprehensive Review
The ninth edition of the TNM classification for thymic epithelial tumors, effective January 2025, introduces updated criteria for tumor extent, lymph node involvement, and metastasis, reinforcing the critical role of imaging in accurate staging and treatment planning.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (2) , e240189
Denoised Ultra-Low-Dose Chest CT to Assess Pneumonia in Individuals Who Are Immunocompromised
Denoised ultra-low-dose CT correctly identified pneumonia and features associated with invasive fungal pneumonia in individuals who were immunocompromised while substantially reducing radiation dose.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (2) , e240189
Denoised Ultra-Low-Dose Chest CT to Assess Pneumonia in Individuals Who Are Immunocompromised
Denoised ultra-low-dose CT correctly identified pneumonia and features associated with invasive fungal pneumonia in individuals who were immunocompromised while substantially reducing radiation dose.
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (12) , e240057
Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists
A comprehensive understanding of the proposed updates in the ninth edition of the TNM staging system for lung cancer enables radiologists to provide accurate clinical radiologic staging, enhancing precision in predicting therapy outcomes and facilitating an individualized approach for each patient.
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (12) , e240057
Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists
A comprehensive understanding of the proposed updates in the ninth edition of the TNM staging system for lung cancer enables radiologists to provide accurate clinical radiologic staging, enhancing precision in predicting therapy outcomes and facilitating an individualized approach for each patient.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (9) , e240196
RadioGraphics Update: The Ninth Edition TNM Staging System for Thymic Epithelial Tumors
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (9) , e240196
RadioGraphics Update: The Ninth Edition TNM Staging System for Thymic Epithelial Tumors
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230091
Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis
Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of image acquisition and measurements,... Thymic imaging is challenging because the imaging appearance of a variety of benign and malignant thymic conditions are similar. CT is the most commonly used modality for mediastinal imaging, while...
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230091
Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis
Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of image acquisition and measurements,... Thymic imaging is challenging because the imaging appearance of a variety of benign and malignant thymic conditions are similar. CT is the most commonly used modality for mediastinal imaging, while...
- 1 March 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (3) , e230221
Diffuse Pulmonary Meningotheliomatosis
- 1 March 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (3) , e230221
Diffuse Pulmonary Meningotheliomatosis
- Open Access
- 1 December 2023
- Published by AME Publishing Company in Mediastinum
- Vol. 7, AB022
AB022. Challenges in thymic imaging
Background: Thymic imaging is challenging as there is overlap in the imaging appearance of a variety of benign and malignant thymic conditions on selected imaging modalities. CT is the most commonly used modality for mediastinal imaging, while MRI and FDG PET/CT are helpful when tailored to the correct indication. Each one of these imaging modalities has its limitations and technical pitfalls which may lead to an incorrect diagnosis and mismanagement. Our objectives are to review indications for thymic imaging, selection of different imaging techniques, common technical and interpretation pitfalls, and post-thymic malignancy treatment pitfalls, and to provide tips to avoid these pitfalls. Methods: We conducted a comprehensive search of our database to identify cases exhibiting potential pitfalls in thymic imaging. Our analysis included cases from a 17-year period, spanning from 2005 to 2022. The review process involved a thorough examination of each case to identify key areas where errors in interpretation could arise. To ensure accuracy, two independent reviewers conducted the analysis and any discrepancies were resolved by consensus. Results: CT’s low contrast resolution hinders the characterization of cystic thymic processes and differentiation between thymic hyperplasia and thymic tumors. MRI can overcome these limitations but is subject to equivocal signal-drop with chemical shift imaging, size limitations, unusual signal for cysts, subtraction artifacts, pseudo-nodularity on T2 weighted imaging (T2WI), early imaging misinterpretation, flow and spatial resolution issues hampering local invasion assessment, and overlap of apparent diffusion coefficient values between malignant and benign thymic entities. FDG PET/CT is not routinely indicated due to some overlap between FDG uptake in thymoma and benign thymic processes. However, it is useful for staging and follow-up of aggressive tumors, particularly for detection of occult metastatic disease. Pitfalls in imaging following treatment of thymic malignancies relate to post-thymectomy sternotomy streak metal artifacts, differentiating between post-surgical thymic bed changes and tumor recurrence, or human error with typical ‘blind spots’ for metastatic disease. Conclusions: Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of imaging acquisition and measurements, and ultimately enhance diagnostic accuracy, ensuring appropriate patient management.
- 1 December 2023
- Published by AME Publishing Company in Mediastinum
- Vol. 7, AB022
Open AccessAB022. Challenges in thymic imaging
Background: Thymic imaging is challenging as there is overlap in the imaging appearance of a variety of benign and malignant thymic conditions on selected imaging modalities. CT is the most commonly used modality for mediastinal imaging, while MRI and FDG PET/CT are helpful when tailored to the correct indication. Each one of these imaging modalities has its limitations and technical pitfalls which may lead to an incorrect diagnosis and mismanagement. Our objectives are to review indications for thymic imaging, selection of different imaging techniques, common technical and interpretation pitfalls, and post-thymic malignancy treatment pitfalls, and to provide tips to avoid these pitfalls. Methods: We conducted a comprehensive search of our database to identify cases exhibiting potential pitfalls in thymic imaging. Our analysis included cases from a 17-year period, spanning from 2005 to 2022. The review process involved a thorough examination of each case to identify key areas where errors in interpretation could arise. To ensure accuracy, two independent reviewers conducted the analysis and any discrepancies were resolved by consensus. Results: CT’s low contrast resolution hinders the characterization of cystic thymic processes and differentiation between thymic hyperplasia and thymic tumors. MRI can overcome these limitations but is subject to equivocal signal-drop with chemical shift imaging, size limitations, unusual signal for cysts, subtraction artifacts, pseudo-nodularity on T2 weighted imaging (T2WI), early imaging misinterpretation, flow and spatial resolution issues hampering local invasion assessment, and overlap of apparent diffusion coefficient values between malignant and benign thymic entities. FDG PET/CT is not routinely indicated due to some overlap between FDG uptake in thymoma and benign thymic processes. However, it is useful for staging and follow-up of aggressive tumors, particularly for detection of occult metastatic disease. Pitfalls in imaging following treatment of thymic malignancies relate to post-thymectomy sternotomy streak metal artifacts, differentiating between post-surgical thymic bed changes and tumor recurrence, or human error with typical ‘blind spots’ for metastatic disease. Conclusions: Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of imaging acquisition and measurements, and ultimately enhance diagnostic accuracy, ensuring appropriate patient management.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (12) , e230130
The Clinician-Educator Pathway in Radiology: What, Why, and How to Start from Residency
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 43 (12) , e230130
The Clinician-Educator Pathway in Radiology: What, Why, and How to Start from Residency
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e220153
Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know
Ongoing discoveries in cancer genomics and epigenomics have revolutionized clinical oncology and precision health care. This knowledge provides unprecedented insights into tumor biology and heterogeneity within a single tumor, among primary and metastatic lesions, and among patients with the same histologic type of cancer. Large-scale genomic sequencing studies also sparked the development of new tumor classifications, biomarkers, and targeted therapies. Because of the central role of imaging in cancer diagnosis and therapy, radiologists need to be familiar with the basic concepts of genomics, which are now becoming the new norm in oncologic clinical practice. By incorporating these concepts into clinical practice, radiologists can make their imaging interpretations more meaningful and specific, facilitate multidisciplinary clinical dialogue and interventions, and provide better patient-centric care. This review article highlights basic concepts of genomics and epigenomics, reviews the most common genetic alterations in cancer, and discusses the implications of these concepts on imaging by organ system in a case-based manner. This information will help stimulate new innovations in imaging research, accelerate the development and validation of new imaging biomarkers, and motivate efforts to bring new molecular and functional imaging methods to clinical radiology. Keywords: Oncology, Cancer Genomics, Epignomics, Radiogenomics, Imaging Markers Supplemental material is available for this article. © RSNA, 2023.
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e220153
Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know
Ongoing discoveries in cancer genomics and epigenomics have revolutionized clinical oncology and precision health care. This knowledge provides unprecedented insights into tumor biology and heterogeneity within a single tumor, among primary and metastatic lesions, and among patients with the same histologic type of cancer. Large-scale genomic sequencing studies also sparked the development of new tumor classifications, biomarkers, and targeted therapies. Because of the central role of imaging in cancer diagnosis and therapy, radiologists need to be familiar with the basic concepts of genomics, which are now becoming the new norm in oncologic clinical practice. By incorporating these concepts into clinical practice, radiologists can make their imaging interpretations more meaningful and specific, facilitate multidisciplinary clinical dialogue and interventions, and provide better patient-centric care. This review article highlights basic concepts of genomics and epigenomics, reviews the most common genetic alterations in cancer, and discusses the implications of these concepts on imaging by organ system in a case-based manner. This information will help stimulate new innovations in imaging research, accelerate the development and validation of new imaging biomarkers, and motivate efforts to bring new molecular and functional imaging methods to clinical radiology. Keywords: Oncology, Cancer Genomics, Epignomics, Radiogenomics, Imaging Markers Supplemental material is available for this article. © RSNA, 2023.